Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) EBITDA (2020 - 2023)

Historic EBITDA for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.0 million.

  • Terns Pharmaceuticals' EBITDA fell 2488.71% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.2 million, marking a year-over-year decrease of 4467.54%. This contributed to the annual value of -$101.9 million for FY2024, which is 66.99% up from last year.
  • Per Terns Pharmaceuticals' latest filing, its EBITDA stood at -$21.0 million for Q4 2023, which was down 2488.71% from -$29.8 million recorded in Q3 2023.
  • Terns Pharmaceuticals' 5-year EBITDA high stood at -$8.8 million for Q4 2020, and its period low was -$29.8 million during Q3 2023.
  • In the last 4 years, Terns Pharmaceuticals' EBITDA had a median value of -$14.1 million in 2021 and averaged -$15.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 527.81% in 2021, then tumbled by 7621.55% in 2023.
  • Terns Pharmaceuticals' EBITDA (Quarter) stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022, then dropped by 24.89% to -$21.0 million in 2023.
  • Its EBITDA stands at -$21.0 million for Q4 2023, versus -$29.8 million for Q3 2023 and -$18.3 million for Q2 2023.